论文部分内容阅读
目的探讨85例乳腺浸润性导管癌中肿瘤干细胞标志物乙醛脱氢酶1(ALDH1)的表达情况及与临床病理特征的关系。方法采用免疫组化法检测乳腺组织芯片85例乳腺浸润性导管癌组织中ALDH1的表达并分析其临床意义。结果 ALDH1在雌激素受体(ER)阴性的乳腺癌中表达率(34.6%)显著高于ER阳性者(12.1%;P=0.024)。不同亚型乳腺癌中存在ALDH1表达的显著差异,其中三阴性乳腺癌中ALDH1的表达较高(50.0%,P=0.034)。ALDH1的表达在不同大小肿块的肿瘤中也存在差异,其中肿块小于2 cm的乳腺癌中ALDH1的表达率最高(50.0%;P=0.040)。而ALDH1的表达与患者年龄、肿瘤分级、淋巴结转移、疾病分期及PR、HER-2状态无关(P>0.05)。结论 ER阴性乳腺癌尤其是三阴性乳腺癌中ALDH1的表达率较高,提示ER阴性乳腺癌中存在较高比例的干细胞,进而有助于更好地理解其预后差的特点。
Objective To investigate the relationship between the expression of ALDH1 and clinicopathological features in 85 cases of invasive ductal carcinoma of the breast. Methods Immunohistochemistry was used to detect the expression of ALDH1 in 85 breast invasive ductal carcinomas and its clinical significance. Results The expression rate of ALDH1 in estrogen receptor (ER) -negative breast cancer was significantly higher than that in ER-positive breast cancer (34.6% vs 12.1%, P = 0.024). There were significant differences in the expression of ALDH1 in different subtypes of breast cancer, of which the expression of ALDH1 was higher in triple negative breast cancer (50.0%, P = 0.034). The expression of ALDH1 was also different in tumors of different size and mass. The expression rate of ALDH1 was the highest (50.0%; P = 0.040) in breast cancer with mass less than 2 cm. However, the expression of ALDH1 was not associated with age, tumor grade, lymph node metastasis, stage of disease and PR, HER-2 status (P> 0.05). Conclusion The high expression of ALDH1 in ER-negative breast cancer, especially in triple-negative breast cancer, suggests that there is a high proportion of stem cells in ER-negative breast cancer, which helps to better understand the poor prognosis.